Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
Metrics: PDF 1164 views | HTML 2017 views | ?
Dirk Walter1,2, Claudia Döring2, Magdalena Feldhahn3, Florian Battke3, Sylvia Hartmann2, Ria Winkelmann2, Markus Schneider2, Katrin Bankov1, Andreas Schnitzbauer4, Stefan Zeuzem1, Martin Leo Hansmann2, Jan Peveling-Oberhag1,2,5
1Department of Internal Medicine I, Johann Wolfgang Goethe-University Hospital, 60590 Frankfurt, Germany
2Dr. Senckenberg Institute of Pathology, Johann Wolfgang Goethe-University Hospital, 60590 Frankfurt, Germany
3CeGaT GmbH, 72076 Tuebingen, Germany
4Department of General and Visceral Surgery, Johann Wolfgang Goethe-University Hospital, 60590 Frankfurt, Germany
5Department for Gastroenterology, Hepatology and Endocrinology, Robert-Bosch Hospital, 70376 Stuttgart, Germany
Dirk Walter, email: firstname.lastname@example.org
Keywords: cholangiocarcinoma, exome sequencing, intratumoral heterogeneity, microsatellite instability, MSH6
Received: October 28, 2016 Accepted: January 16, 2017 Published: January 27, 2017
No personalized therapy regimens could demonstrate a benefit in survival of intrahepatic cholangiocarcinoma (iCCA). Since genetic heterogeneity might influence single biopsy based targeted therapy or the outcome of clinical trials, aim of the present study was to investigate intratumoral heterogeneity of iCCA by whole exome sequencing. Therefore, samples from tumor center and tumor periphery of large iCCA lesions as well as a control from healthy liver tissue were obtained from four patients and whole exome sequencing was performed. Mutations that occurred only in the tumor center or periphery were defined as private, whereas mutations present in both samples were regarded as common. A mean of 3 non-synonymous private mutations (range 0–14) per sample compared to 33,3 common mutations per sample (range 24–41) was identified. Mean percentage of non-synonymous private mutations per sample was 12% (range 0–58). In all samples of patient 1-3 as well as the central sample of patient 4 ≤ 10% private mutations were found, whereas 58% of private mutations were identified in the peripheral sample of patient 4. In this sample a private mutation in the DNA mismatch repair protein MSH6 could be identified most likely causing the high amount of private mutations. No substantial intratumoral heterogeneity was found in copy number variation analysis. In conclusion, iCCA show a small but distinct intratumoral heterogeneity. Somatic mutations in mismatch repair proteins might contribute significantly to increased spatial tumor burden and thereby may influence clinical management.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.